Antal Berenyi has a diverse work experience in the field of neuroscience and medical device development. Antal started their career in 2010 as a Postdoctoral Fellow at Rutgers University. In 2013, they became the Principal Investigator at MTA-SZTE "Momentum" Oscillatory Neural Networks Research Group, where they led a joint research team investigating the pathophysiology of epileptic seizures and memory processes. Alongside this, they also served as an Adjunct Assistant Professor at NYU Langone Medical Center. In 2018, Berenyi founded Neunos Ltd, a medical device developer startup aimed at developing a brain stimulator to treat drug-resistant epileptic seizures. Antal also served as the Chief Science Officer (CSO) of the company. Beginning in 2020, Berenyi became a Principal Investigator at the HCEMM, focusing on molecular medicine. Finally, they are the owner and CEO of Amplipex Ltd, a company that develops and manufactures biosignal amplifier systems for neuroscience research.
Antal Berenyi completed their education in a chronological manner. Antal first obtained a Doctor of Medicine (MD) degree from the University of Szeged, specializing in General medicine. Following this, they pursued a Doctor of Philosophy (PhD) degree in Neuroscience at the same institution. Additionally, during the same period, they also attained a degree in Medical economics, with a focus on Neuroscience.
This person is not in any teams
HCEMM / Hungarian Centre of Excellence for Molecular Medicine
The Hungarian Centre of Excellence for Molecular Medicine – HCEMM - is a gamechanger organization which catalyzes reforming changes in the research culture and makes an impact in the regional development of Hungarian knowledge regions. The organisational and management model ensures autonomy and scientific excellence with an international evaluation system. Research groups are pursuing in cross-cutting fields and are reviewed every 5 years in order to ensure scientific excellence. HCEMM focuses on and supports molecular medicine-oriented research activities targeting key, highly prevalent ageing-related non-communicable diseases. HCEMM was created by the union of the University of Szeged, the Semmelweis University and the Biological Research Center of the Hungarian Academy of Sciences. They were joined by the National Research, Innovation and Development Office representing the Hungarian Government as project coordinator and by the European Molecular Biology Laboratory (EMBL) as an advanced scientific institution. Supported by EU Programme: H2020-EU.4.a. - Teaming of excellent research institutions and low performing RDI regions. Project starting date was 1 April 2017.